Immucell Stock Today
| ICCC Stock | USD 6.24 0.13 2.13% |
PerformanceWeak
| Odds Of DistressSmall
|
ImmuCell is trading at 6.24 as of the 10th of February 2026, a 2.13% increase since the beginning of the trading day. The stock's open price was 6.11. ImmuCell has about a 27 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 12th of November 2025 and ending today, the 10th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of April 1987 | Category Healthcare | Classification Health Care |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. The company has 9.05 M outstanding shares of which 10.92 K shares are currently shorted by private and institutional investors with about 0.24 trading days to cover. More on ImmuCell
Moving against ImmuCell Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ImmuCell Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Michael Brigham | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBy employing borrowed capital, ImmuCell can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on ImmuCell's use of financial leverage and reveals what portion of ImmuCell's asset base relies on creditor financing.
| |||||
ImmuCell (ICCC) is traded on NASDAQ Exchange in USA and employs 77 people. ImmuCell is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 54.73 M. ImmuCell conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.05 M outstanding shares of which 10.92 K shares are currently shorted by private and institutional investors with about 0.24 trading days to cover.
ImmuCell currently holds about 11.04 M in cash with 357.9 K of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.43.
Check ImmuCell Probability Of Bankruptcy
Ownership AllocationThe market capitalization of ImmuCell is $54.73 Million. ImmuCell secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check ImmuCell Ownership Details
ImmuCell Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Strategic Investment Advisors Inc | 2025-06-30 | 31 K | |
| Hightower Advisors, Llc | 2025-06-30 | 21.4 K | |
| Prosperity Planning, Inc. | 2025-06-30 | 16 K | |
| Blackrock Inc | 2025-06-30 | 15.8 K | |
| Mesirow Fin Investmt Mgmt Intl Equity | 2025-06-30 | 12.2 K | |
| Essex Financial Services, Inc. | 2025-06-30 | 11 K | |
| Ubs Group Ag | 2025-06-30 | 8.4 K | |
| Hm Payson & Co | 2025-03-31 | 4 K | |
| Bank Of America Corp | 2025-06-30 | 2.1 K | |
| Vanguard Group Inc | 2025-06-30 | 308.7 K | |
| Renaissance Technologies Corp | 2025-06-30 | 160 K |
ImmuCell Historical Income Statement
ImmuCell Stock Against Markets
ImmuCell Corporate Executives
Elected by the shareholders, the ImmuCell's board of directors comprises two types of representatives: ImmuCell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmuCell. The board's role is to monitor ImmuCell's management team and ensure that shareholders' interests are well served. ImmuCell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmuCell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Fiori | Secretary, CFO | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Will Biotechnology sector continue expanding? Could ImmuCell diversify its offerings? Factors like these will boost the valuation of ImmuCell. Market participants price ImmuCell higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ImmuCell data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.63) | Earnings Share 0.21 | Revenue Per Share | Quarterly Revenue Growth 0.178 | Return On Assets |
Understanding ImmuCell requires distinguishing between market price and book value, where the latter reflects ImmuCell's accounting equity. The concept of intrinsic value - what ImmuCell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ImmuCell's price substantially above or below its fundamental value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, ImmuCell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.